Nonmalignant Disorders of Leukocytes: A Comprehensive Review

Abstract

Leukocytes, or white blood cells, constitute the fundamental cellular defense mechanism against microbial invasion and mediate diverse immunological and inflammatory responses. This review examines the nonmalignant disorders affecting neutrophils, monocytes, macrophages, and eosinophils, encompassing quantitative abnormalities (neutrophilia, neutropenia, eosinophilia) and qualitative functional defects. The pathophysiology, diagnostic approaches, and contemporary therapeutic strategies are discussed, with particular emphasis on the role of hematopoietic growth factors and evidence-based management protocols.

Keywords: leukocytes, neutropenia, neutrophilia, eosinophilia, phagocytic disorders, colony-stimulating factors

1. Introduction

The hematopoietic system produces approximately 1 × 10⁹ neutrophils per kilogram per day, with these cells representing the first line of defense against bacterial and fungal pathogens (Dale, 2004). The total white blood cell (WBC) count in peripheral blood normally ranges from 4,300 to 10,000/mm³, with neutrophils constituting the predominant fraction (Table 1). Disorders of leukocyte number or function significantly compromise host immunity, resulting in increased susceptibility to infections of varying severity.

The diagnostic evaluation of suspected phagocytic cell disorders requires systematic assessment of both quantitative parameters (absolute cell counts) and qualitative functions (adherence, chemotaxis, phagocytosis, oxidative metabolism). This review synthesizes current understanding of nonmalignant leukocyte disorders, their pathogenesis, and therapeutic interventions.

2. Neutrophil Physiology and Kinetics

2.1 Production and Maturation

Neutrophil development in the bone marrow spans approximately 10–14 days, progressing through distinct morphological stages: myeloblasts, promyelocytes, myelocytes (mitotic compartment), and subsequently metamyelocytes, band forms, and segmented neutrophils (postmitotic pool) (Figure 2). Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) serve as principal regulatory cytokines, with G-CSF selectively stimulating neutrophil lineage differentiation.

The bone marrow harbors approximately 90% of the body's neutrophils, with fewer than 10% circulating in peripheral blood. These circulating neutrophils are partitioned equally between the circulating pool and the marginating pool, with dynamic equilibrium maintained through adhesion molecule interactions. Demargination, mediated by epinephrine or exercise-induced hemodynamic changes, can rapidly double the circulating neutrophil count within minutes.

2.2 Functional Mechanisms

Neutrophil-mediated host defense comprises sequential stages: adherence to endothelium, chemotaxis toward inflammatory foci, recognition and phagocytosis of opsonized pathogens, degranulation, and oxidative killing (Figure 3). The respiratory burst, catalyzed by NADPH oxidase, generates superoxide (O₂⁻), hydrogen peroxide (H₂O₂), hydroxyl radicals (OH•), and hypochlorous acid (HOCl)—all potent microbicidal agents.

Adherence involves selectin-mediated rolling (L-selectin/sialyl-Lewisˣ interactions with E-selectin/P-selectin) followed by β₂-integrin (CD11/CD18) activation and firm adhesion to intercellular adhesion molecules (ICAMs) (Figure 4). Chemotaxis is directed by complement-derived C5a, leukotriene B₄, interleukin-8 (IL-8), and various chemokines.

3. Disorders of Neutrophil Number

3.1 Neutrophilia

Neutrophilia, defined as neutrophil count exceeding the upper normal limit, most commonly arises secondary to inflammation, physiological stress, or corticosteroid therapy. Cigarette smoking induces neutrophilia through airway inflammation. Extreme neutrophilia (>30,000–50,000/mm³), termed leukemoid reaction, occurs with severe infections, sepsis, hemorrhagic shock, and extensive tissue injury.

Primary neutrophilia encompasses myeloproliferative disorders, particularly chronic myeloid leukemia (CML), characterized by splenomegaly, left-shifted granulocytic precursors in peripheral blood, basophilia, and reduced leukocyte alkaline phosphatase (LAP) score. Hereditary neutrophilias are rare benign conditions.

Diagnostic approach: When neutrophilia cannot be attributed to infection, inflammation, or glucocorticoid therapy, myeloproliferative disease must be excluded. Bone marrow examination, cytogenetic analysis (including bcr-abl testing for CML), and LAP scoring guide differential diagnosis.

3.2 Neutropenia

Neutropenia, conventionally defined as neutrophil count <1,800/mm³ (or <1,000/mm³ in certain ethnic populations), represents one of the most clinically significant leukocyte disorders. The risk of serious bacterial infection increases substantially when counts fall below 500/mm³ (0.5 × 10⁹/L).

Etiological Classification

Secondary neutropenia predominates in clinical practice:

·        Drug-induced neutropenia: The most common cause in adults, occurring through dose-dependent myelosuppression (cytotoxic chemotherapy agents) or idiosyncratic immune-mediated destruction. Offending agents include antithyroid drugs, anticonvulsants, antibiotics (penicillins, sulfonamides), and antipsychotics (Table 2).

·        Infection-associated neutropenia: Viral infections (HIV, hepatitis, infectious mononucleosis, measles) frequently cause mild neutropenia through diverse mechanisms including direct marrow suppression, autoantibody formation, and accelerated apoptosis. Severe bacterial infections may induce neutropenia via endotoxemia-mediated neutrophil consumption exceeding marrow reserve.

·        Autoimmune neutropenia: Occurs as an isolated phenomenon or secondary to systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, and Felty syndrome (rheumatoid arthritis with splenomegaly and neutropenia). Large granular lymphocyte (LGL) expansion mediates neutropenia through Fas ligand or interferon-γ production in some cases.

·        Splenic sequestration: Hypersplenism from cirrhosis, sarcoidosis, or congestive pathologies causes mild neutropenia typically accompanied by thrombocytopenia.

Primary (congenital) neutropenia includes:

·        Severe congenital neutropenia (Kostmann syndrome): Autosomal recessive or sporadic; characterized by severe neutropenia from birth with recurrent infections; marrow shows promyelocyte arrest; G-CSF receptor mutations identified in some cases.

·        Cyclic neutropenia: Regular 21-day oscillations in blood cell counts, particularly neutrophils and monocytes; autosomal dominant with locus at 19p13.3.

·        Shwachman-Diamond syndrome: Autosomal recessive (7q11); neutropenia with pancreatic insufficiency and potential marrow failure progression.

·        Chédiak-Higashi syndrome: Autosomal recessive (1q42); partial albinism, recurrent infections, giant cytoplasmic granules, and defective chemotaxis.

Clinical Manifestations and Management

Patients with acute severe neutropenia frequently present with fever (febrile neutropenia), requiring immediate empirical broad-spectrum antibiotic therapy. Risk stratification considers neutrophil count, duration of neutropenia, comorbidities (diabetes, renal failure), and mucocutaneous barrier integrity.

Evidence-based guidelines (Infectious Diseases Society of America; American Society of Clinical Oncology) recommend:

1.     Immediate monotherapy with antipseudomonal β-lactams (ceftazidime, imipenem) or duotherapy with aminoglycoside plus piperacillin

2.     Vancomycin addition for suspected gram-positive sepsis

3.     Antifungal consideration for persistent fever after 3–5 days

4.     G-CSF or GM-CSF as adjunctive therapy in high-risk, severely ill patients

Chronic neutropenia management: G-CSF (1–5 mcg/kg/day) demonstrates proven efficacy for congenital, idiopathic, and cyclic neutropenia, substantially reducing infection frequency. Prophylactic antibiotics lack established benefit and promote resistant organism colonization.

4. Disorders of Neutrophil Function

Patients with recurrent severe infections despite normal neutrophil counts require evaluation for functional defects (Table 5). The diagnostic algorithm (Figure 5) proceeds from history and physical examination through specialized testing:

·        Adherence defects: Leukocyte adhesion deficiency (LAD) type I (CD11/CD18 deficiency, AR, 21q22.3) and type II (sialyl-Lewisˣ deficiency); characterized by neutrophilia, absent pus formation, and delayed umbilical cord separation.

·        Granule defects: Chédiak-Higashi syndrome (giant granules, defective chemotaxis); specific granule deficiency (absent secondary granules, abnormal migration and respiratory burst).

·        Respiratory burst defects: Chronic granulomatous disease (CGD)—the most clinically significant; mutations in NADPH oxidase subunits (gp91^phox, p22^phox, p47^phox, p67^phox) prevent superoxide generation; diagnosed by nitroblue tetrazolium (NBT) test or dihydrorhodamine flow cytometry; treated with interferon-γ prophylaxis, antibiotics, and bone marrow transplantation.

·        Glucose-6-phosphate dehydrogenase (G6PD) deficiency: X-linked; reduced NADPH availability compromises oxidative killing.

·        Myeloperoxidase deficiency: Autosomal recessive; generally mild clinical phenotype due to compensatory killing mechanisms.

5. Disorders of Monocytes and Macrophages

5.1 Physiological Context

Monocytes differentiate from bone marrow progenitors through monoblast and promonocyte stages, subsequently populating tissues as macrophages (Kupffer cells, alveolar macrophages, osteoclasts, dendritic cells, Langerhans cells). Beyond phagocytosis, mononuclear phagocytes orchestrate immune responses through antigen presentation (MHC class II), cytokine production, and involvement in wound healing and tissue remodeling.

5.2 Histiocytic Syndromes

Langerhans cell histiocytosis (LCH): A clonal proliferative disorder of dendritic cells affecting children and young adults; spectrum ranges from solitary eosinophilic granuloma to multisystem Letterer-Siwe disease. Clinical manifestations include bone lesions, diabetes insipidus (pituitary infiltration), skin involvement, and pulmonary disease. Treatment involves surgery, radiation, or chemotherapy (vinblastine, methotrexate, cladribine) depending on extent.

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Chronic painless massive lymphadenopathy, predominantly cervical; histology shows emperipolesis; usually self-limited but may require intervention for critical organ involvement.

Hemophagocytic lymphohistiocytosis (HLH): A life-threatening hyperinflammatory syndrome with fever, pancytopenia, hepatosplenomegaly, and hemophagocytosis; familial forms linked to perforin gene mutations; treatment requires immunochemotherapy (etoposide, dexamethasone) and allogeneic transplantation for genetic cases.

5.3 Lysosomal Storage Diseases

Macrophage lysosomal dysfunction underlies storage diseases including Gaucher disease (glucocerebrosidase deficiency), Niemann-Pick disease (sphingomyelinase deficiency), and mucopolysaccharidoses (Table 6). Enzyme replacement therapy (imiglucerase for Gaucher disease) and bone marrow transplantation represent current therapeutic modalities.

6. Disorders of Eosinophils

6.1 Eosinophil Biology

Eosinophils, characterized by bilobed nuclei and distinctive electron-dense crystalloid granules containing major basic protein (MBP) and eosinophil cationic protein (ECP), function primarily in helminth immunity and allergic inflammation. IL-5 serves as the critical cytokine for eosinophil production and activation.

6.2 Eosinophilia

Eosinophilia (>700/mm³) presents a broad differential diagnosis encompassing allergic disorders, parasitic infections (particularly tissue-invasive helminths), dermatologic and pulmonary diseases, collagen vascular disorders, malignancies, and immunodeficiency states.

6.3 Hypereosinophilic Syndrome (HES)

HES is defined by sustained eosinophilia (>1,500/mm³ for >6 months) with evidence of end-organ damage. Clinical features include rash, fever, pulmonary symptoms, and characteristic endomyocardial fibrosis with valvular dysfunction. Recent molecular characterization identified the FIP1L1-PDGFRA fusion kinase, establishing imatinib mesylate as a targeted therapeutic option. Alternative treatments include corticosteroids, hydroxyurea, and interferon-α.

7. Diagnostic Algorithm for Suspected Phagocytic Cell Disorders

Systematic evaluation (Figure 5) integrates:

1.     Comprehensive history: Medications, infections, family history, autoimmune disease, HIV status

2.     Physical examination: Skin, oropharynx, lymph nodes, hepatosplenomegaly

3.     Laboratory studies: CBC with differential, platelet count, peripheral smear morphology

4.     Specialized testing: Bone marrow examination, immunoglobulin levels, complement studies, flow cytometry, NBT test, chemotaxis assays

5.     Genetic testing: Available for several congenital disorders (see GeneTests directory)

8. Conclusion

Nonmalignant leukocyte disorders encompass a spectrum of quantitative and qualitative abnormalities with significant infectious morbidity. Advances in molecular genetics have elucidated pathogenetic mechanisms for many congenital disorders, while recombinant hematopoietic growth factors (particularly G-CSF) have transformed management of neutropenia. The diagnostic approach requires methodical evaluation of cell counts, morphology, and specialized functional assays, guided by clinical presentation and family history. Future directions include gene therapy for inherited disorders and refined targeted therapies for eosinophilic and histiocytic syndromes.

References

Dale, D. C. (2004). Nonmalignant disorders of leukocytes. ACP Medicine: Hematology, VII, 1–16. WebMD, Inc.